News Gilead Sciences, Inc.

Equities

GILD

US3755581036

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-17 pm EDT			5-day change	1st Jan Change
73.3 ^USD	+2.32%		+6.62%	-9.52%

Jul. 17	Gilead Sciences Chief Medical Officer Merdad Parsey to Leave	MT
Jul. 17	Gilead Sciences Chief Medical Officer to Step Down	DJ

Summary

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Gilead Sciences Chief Medical Officer Merdad Parsey to Leave	Jul. 17	MT
Gilead Sciences Chief Medical Officer to Step Down	Jul. 17	DJ
Chief Medical Officer Merdad Parsey to Leave Gilead Early 2025	Jul. 17	BU
Merdad Parsey to Leave Gilead Sciences, Inc. as Chief Medical Officer, Effective Early 2025	Jul. 17	CI
Gilead to Highlight Landmark Progress in Research Across HIV Prevention, Treatment and Cure Programs at AIDS 2024	Jul. 16	BU
Goldman Sachs Adjusts Price Target on Gilead Sciences to $71 From $73, Maintains Neutral Rating	Jul. 16	MT
Morgan Stanley Adjusts Price Target on Gilead Sciences to $74 From $78	Jul. 11	MT
New HIV Drug Can Only Offer Hope of Ending Aids If All Have Access, UNAIDS Says	Jul. 11	AQ
RBC Cuts Price Target on Gilead Sciences to $71 From $74, Keeps Sector Perform Rating	Jul. 09	MT
Raymond James Upgrades Gilead Sciences to Outperform From Market Perform, Price Target is $93	Jul. 08	MT
HIV Breakthrough - Drug Trial Shows Injection Twice a Year Is 100 Percent Effective Against Infection [analysis]	Jul. 03	AQ
HOOKIPA Pharma Reports First Patient Dosed in HIV Treatment Study	Jul. 01	MT
HOOKIPA Pharma Inc. Announces First Person Dosed in Phase 1b Clinical Trial of HB-500 for the Treatment of HIV	Jul. 01	CI
Gilead Benefit Helps Employees Navigate Cancer Care	Jul. 01	AQ
Gilead Sciences, Inc Announces New Data Support the Use of BICtegravir Tablet Regimen to Treat People with HIV and Individuals with HIV/HBV-Coinfection in Asia	Jun. 26	CI
Redburn Atlantic Adjusts Price Target on Gilead Sciences to $119 From $117	Jun. 26	MT
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE397 and Trodelvy Combination in MTAP-Deletion Bladder Cancer	Jun. 25	CI
Jefferies Adjusts Price Target on Gilead Sciences to $85 From $80	Jun. 24	MT
Gilead small molecule demonstrates strong capability for HIV prevention	Jun. 21	AQ
Tech overload on Wall Street	Jun. 21

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Gilead Sciences, Inc.

Equities

GILD

US3755581036

Summary

Filters